Isolated limb perfusion with melphalan for melanoma

Journal of Surgical Oncology

Volumn 109, Issue 4, 2014, Pages 332-337

  Nieweg, Omgo E ^a   Kroon, Bin B R ^b  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

limb perfusion; metastases; regional chemotherapy; review

Indexed keywords

LIMB PERFUSION; METASTASES; REGIONAL CHEMOTHERAPY; REVIEW;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; MELANOMA; MELPHALAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893914823     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23558     Document Type: Review

References (67)

1. Creech O, Jr., Krementz ET, Ryan RF, et al.: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-632.
2. Benckhuijsen C, Kroon BBR, van Geel AN, et al.: Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol 1988; 14: 157-163.
3. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002; 9: 968-974.
4. Aigner K, Hild P, Henneking K, et al.: Regional perfusion with cis-platinum and dacarbazine. Recent Results Cancer Res 1983; 86: 239-245.
5. Vaglini M, Belli F, Santinami M, et al.: Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma. Ann Surg Oncol 1995; 2: 61-70.
6. Sanki A, Kam PC, Thompson JF:, Long-term results of hyperthermic, isolated limb perfusion for melanoma: A reflection of tumor biology. Ann Surg 2007; 245: 591-596.
7. Beasley GM, Riboh JC, Augustine CK, et al.: Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol 2011; 29: 1210-1215.
8. Beasley GM, Tyler DS:, Standardizing regional therapy: Developing a consensus on optimal utilization of regional chemotherapy treatments in melanoma. Ann Surg Oncol 2011; 18: 1814-1848.
9. Vaglini M, Belli F, Marolda R, et al.: Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities. Eur J Surg Oncol 1987; 13: 127-129.
10. Hoekstra HJ, Schraffordt Koops H, de Vries LG, et al.: Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993; 72: 1224-1229.
11. Bonenkamp JJ, Thompson JF, De Wilt JH, et al.: Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004; 30: 1107-1112.
12. Rossi CR, Russano F, Mocellin S, et al.: TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: A pilot trial. Ann Surg Oncol 2008; 15: 1218-1223.
13. Kroon BBR, Noorda EM, Vrouenraets BC, et al.: Isolated limb perfusion for melanoma. In:, Aigner KR, Stephens FO, Vogl TJ, Padberg W, editors. Regionale therapie maligner tumoren. Heidelberg, Germany: Springer; 2013; 299-311.
14. Klaase JM, Kroon BBR, van Geel AN, et al.: Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993; 80: 1124-1126.
15. Kroon BBR:, Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 1988; 14: 101-110.
16. Klaase JM, Kroon BBR, Eggermont AMM, et al.: A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1995; 31A: 58-63.
17. Hahn GM:, Hyperthermia cancer. New York, London: Plenum Press; 1982.
18. Vrouenraets BC, Klaase JM, Nieweg OE, et al.: Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14: 224-231.
19. van der Zee J, Kroon BBR, Nieweg OE, et al.: Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion. Eur J Cancer 1997; 33: 1546-1550.
20. Kroon BBR, Klaase JM, Van Geel AN, et al.: Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 1992; 4: 223-226.
21. van der Zee J, Kroon BBR:, Isolated limb perfusion for malignant melanoma; possibly better results with high dose hyperthermia. Int J Hyperthermia 2008; 24: 602-603.
22. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb. Melanoma Res 2003; 13: 395-399.
23. Vrouenraets BC, Nieweg OE, Kroon BBR:, Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 1996; 83: 1319-1328.
24. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004; 139: 1237-1242.
25. Di Filippo F, Calabro A, Giannarelli D, et al.: Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551-2561.
26. Klaase JM, Kroon BBR, van Geel AN, et al.: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of limbs treated with regional isolated perfusion using melphalan. Surgery 1994; 115: 39-45.
27. Noorda EM, van Kreij RH, Vrouenraets BC, et al.: The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol 2007; 33: 776-782.
28. Kapma MR, Vrouenraets BC, Nieweg OE, et al.: Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. Eur J Surg Oncol 2005; 31: 95-99.
29. Fraker DL, Alexander HR, Ross MI, et al.: A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma. Ann Surg Oncol 2013; 9: S8.
30. Takkenberg RB, Vrouenraets BC, van Geel AN, et al.: Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol 2005; 91: 107-111.
31. Klaase JM, Kroon BBR, van Geel AN, et al.: A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993; 71: 2990-2994.
32. Thompson JF, Hunt JA, Shannon KF, et al.: Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903-907. et al.
33. Strobbe LJ, Nieweg OE, Kroon BBR:, Carbon dioxide laser for cutaneous melanoma metastases: Indications and limitations. Eur J Surg Oncol 1997; 23: 435-438.
34. Mali B, Jarm T, Snoj M, et al.: Antitumor effectiveness of electrochemotherapy: A systematic review and meta-analysis. Eur J Surg Oncol 2013; 39: 4-16.
35. Thompson JF, Hersey P, Wachter E:, Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008; 18: 405-411.
36. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al.: Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995; 345: 540-543.
37. Klop WM, Vrouenraets BC, van Geel BN, et al.: Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 1996; 182: 467-472.
38. Schraffordt Koops H, Vaglini M, Suciu S, et al.: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906-2912.
39. Hafström L, Rudenstam C-M, Blomquist E, et al.: Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991; 9: 2091-2094.
40. Noorda EM, Takkenberg B, Vrouenraets BC, et al.: Isolated limb perfusion prolongs the limb recurrence-free interval after episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol 2004; 491-499.
41. Thomas DR, Ritchie CS:, Preoperative assessment of older adults. J Am Geriatr Soc 1995; 43: 811-821.
42. Zenilman ME:, Surgery in the elderly. Curr Probl Surg 1998; 35: 99-179.
43. Pawlik TM, Ross MI, Johnson MM, et al.: Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12: 587-596.
44. Lai DTM, Ingvar C, Thompson JF:, The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat 1993; 6: 36-39.
45. Olieman AF, Schraffordt Koops H, Geertzen JH, et al.: Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol 1994; 1: 382-388.
46. Cavaliere R, Di Filippo F, Giannarelli D, et al.: Hyperthermic antiblastic perfusion in the treatment of local recurrence or "in-transit" metastases of limb melanoma. Semin Surg Oncol 1992; 8: 374-380.
47. Vrouenraets BC, Hart AAM, Eggermont AMM, et al.: Relation between limb toxicity and treatment outcome after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999; 188: 522-530.
48. Wieberdink J, Benckhuysen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910.
49. Vrouenraets BC, Kroon BBR, Klaase JM, et al.: Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 1995; 5: 425-431.
50. Klaase JM, Kroon BBR, Beijnen JH, et al.: Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 1994; 70: 151-153.
51. Klaase JM, Kroon BBR, van Slooten GW, et al.: Relation beween calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma. Reg Cancer Treat 1992; 4: 309-312.
52. Scott RN, Blackie R, Kerr DJ, et al.: Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In:, Jakesz H, Rainer H, editors. Progress in regional cancer therapy. Berlin, Heidelberg: Springer-Verlag; 1990; pp. 195-217.
53. Vrouenraets BC, Klaase JM, Kroon BBR, et al.: Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995; 130: 43-47.
54. van Geel AN, van Wijk J, Wieberdink J:, Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer 1989; 63: 1092-1096.
55. Knorr C, Melling N, Goehl J, et al.: Long-term functional outcome after hyperthermic isolated limb perfusion (HILP). Int J Hyperthermia 2008; 24: 409-414.
56. Vrouenraets BC, Eggermont AMM, Klaase JM, et al.: Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol 1994; 20: 681-685.
57. Sonneveld EJ, Vrouenraets BC, van Geel BN, et al.: Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 1996; 22: 521-527.
58. Beasley GM, Ross MI, Tyler DS:, Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia 2008; 24: 301-309.
59. Tyler DS, Yoshimoto Y, Grubbs E:, Novel strategies to overcome chemoresistance in regional melanoma therapy by systemic modulation of tumor proteins. Melanoma Res 2013; 16: S100.
60. Lienard D, Ewalenko P, Delmotte J-J, et al.: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
61. Kroon HM, Moncrieff M, Kam PC, et al.: Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008; 15: 3003-3013.
62. Kroon HM, Moncrieff M, Kam PC, et al.: Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 2009; 16: 1184-1192.
63. Brady MS, Brown K, Patel A, et al.: A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13: 1123-1129.
64. Beasley GM, Petersen RP, Yoo J, et al.: Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008; 15: 2195-2205.
65. Beasley GM, Caudle A, Petersen RP, et al.: A multi-institutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg 2009; 208: 706-715.
66. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
67. Robert C, Thomas L, Bondarenko I, et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.